Impact of COVID-19 on initiation of biologic therapy prescriptions for chronic inflammatory diseases.

Richette, Pascal; Allez, Matthieu; Descamps, Vincent; Perray, Lucas; Pilet, Simon; Latourte, Augustin; Maravic, Milka

Richette, Pascal; Allez, Matthieu; Descamps, Vincent; Perray, Lucas; Pilet, Simon; Latourte, Augustin; Maravic, Milka.

Richette P; Rheumatology department, Lariboisière Hospital, AP-HP, 2, rue Ambroise Paré, 75010 Paris, France; Inserm U1132, Paris University, Paris, France. Electronic address: pascal.richette@aphp.fr.
Allez M; Gastro Enterology department, St-Louis Hospital, AP-HP, Paris, France.
Descamps V; Dermatology department, Bichat Hospital, AP-HP, Paris, France.
Perray L; IQVIA, La Défense, France.
Pilet S; IQVIA, La Défense, France.
Latourte A; Rheumatology department, Lariboisière Hospital, AP-HP, 2, rue Ambroise Paré, 75010 Paris, France; Inserm U1132, Paris University, Paris, France.
Maravic M; IQVIA, La Défense, France.

Joint Bone Spine ; 89(1): 105253, 2022 01.

Article in English | MEDLINE | ID: covidwho-1327067

Subject(s)

Biological Products; COVID-19; Biological Products/therapeutic use; Biological Therapy; Humans; Prescriptions; SARS-CoV-2

Keywords

Biologics; COVID-19; Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Biological Products / COVID-19 Type of study: Experimental Studies Limits: Humans Language: English Journal: Joint Bone Spine Journal subject: Rheumatology Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google